With completion of the renovation, Microbiologics has expanded its custom virology solutions to include Biosafety Level 3 (BSL-3) antiviral services.
With these new capabilities, Microbiologics has launched a menu of cell-based services for SARS-CoV-2 to assist assay developers, evaluate therapeutic solutions and vaccines, and provide inactivated intact virus to researchers and diagnostic companies.
Microbiologics has also expanded its viral capabilities to include reverse genetics systems to create recombinant viruses, increased in-vitro assay capabilities, including cytopathic effect screening, hemagglutination-inhibition testing, neutralization assays, and yield-reduction assays.
The newly renovated space also allows for increased capacity for viral propagation of high-titer stock materials. Microbiologics has also recently completed its process for ISO 13485 accreditation at the San Diego Facility.
Microbiologics is a global provider of infectious disease biomaterials. Microbiologics has provided clinical, food, water, pharmaceutical and cosmetic laboratories with reliable, ready-to-use microbial reference materials for nearly 50 years.
The company has a distribution network that reaches more than 140 countries worldwide.
Microbiologics acquired San Diego based Virapur in 2017 expanding its research and development support services to therapeutics, vaccines and gene therapy, as well as broaden its viral molecular controls portfolio.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer